Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05136833
Other study ID # AC-R6
Secondary ID 2021-003301-22
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date December 1, 2021
Est. completion date December 31, 2022

Study information

Verified date July 2022
Source Archivel Farma S.L.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is an exploratory clinical trial to evaluate the efficacy and safety of the treatment with a vaccine against tuberculosis (RUTI®) given at the same time as standard treatment in patients with tuberculosis. It is a prospective, randomized (1:1), double-blind, multicentre, placebo-controlled clinical phase IIb trial.


Description:

Patients will be randomized (1: 1) to receive an inoculation of RUTI® or placebo at the same time that standard treatment is started. The standard TB treatment will continue after RUTI® or placebo administration according to SOC guidelines. All the patients will be followed up 6 months after the vaccination or until the end of SOC treatment. Once all the patients have completed the week 2 follow-up, a Data Safety Monitoring Board (DSMB) will be established to review all relevant safety and toxicity data.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 31, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults (females and males) aged = 18. 2. Written informed consent in a language they understand. This includes informed consent to be in the trial and informed consent to collect specimens. 3. Laboratory confirmed pulmonary TB (with or without extrapulmonary involvement) defined as a hard copy of a sputum laboratory result that reports Mtb detection by sputum-microscopy smear-positive at least 1+, rapid molecular assay or mycobacterial culture. 4. Patients who have not received any anti-tubercular treatment in the last 24 hours. 5. Females of non-childbearing potential: at least 2 years post-menopausal or surgically sterile (e.g. tubal ligation). 6. Females of childbearing potential (including females less than 2 years post-menopausal) must have a negative pregnancy test at enrolment and must agree to use highly effective methods of birth control (i.e. diaphragm plus spermicide or male condom plus spermicide, oral contraceptive in combination with a second method, contraceptive implant, injectable contraceptive, indwelling intrauterine device, sexual abstinence, or a vasectomized partner) while participating in the study. 7. Males must agree to use a double-barrier method of contraception (condom plus spermicide or diaphragm plus spermicide) at least 1 month after RUTI/placebo vaccination; or the male patient or his female partner must be surgically sterile (e.g. vasectomy, tubal ligation) or the female partner must be post-menopausal. 8. The patient must be willing and able to attend all study visits and comply with all study procedures. Exclusion Criteria: 1. Unable to provide written informed consent. 2. Women reported, or detected, or willing to be pregnant during the trial period. 3. Severity of illness precluding full evaluation: expected early death, evidenced by respiratory failure, low blood pressure, WHO performance score 3-4. 4. Bodyweight < 40kg. 5. Evidence of rifampicin resistance via GeneXpert. 6. Unstable Diabetes Mellitus as a poor metabolic control within the past 12 months. 7. For HIV infected subjects if the CD4+ count <250 cells/µL. 8. Major co-morbid conditions or any other finding which in the opinion of the investigator would compromise the protocol compliance or significantly influence the interpretation of results (i.e. cancer, immunodeficiency of any nature including treatment with immunosuppressant drugs and excluding HIV infection). 9. Any of the following laboratory parameters: - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN); - Total bilirubin > 2 x ULN; - Neutrophil count = 500 neutrophils / mm3; - Platelet count < 50,000 platelets / mm3. 10. Alcohol use: potential participant either self-reports or in the investigator's opinion that the patient drinks more than an average of four units/day over a usual week or is a binge drinker (men: 5 or more drinks; women: consume 4 or more drinks, in about 2 hours). 11. Documented allergy to TB vaccines or any of the study treatment excipients, notably, to the RUTI® vaccine. 12. Concurrent enrolment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
RUTI® vaccine
Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
Placebo
Normal saline will be used as a placebo.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Archivel Farma S.L. Fundació Institut Germans Trias i Pujol

Outcome

Type Measure Description Time frame Safety issue
Other IFN-? production of ex vivo stimulated peripheral blood mononuclear cells (PBMC) (Exploratory endpoint for immunogenicity outcomes 1) Immunogenic properties of the intervention group will be compared to the control group assessed by the evaluation of IFN-? production of specific immune cells. Up to week 24
Other The summative ability of PBMCs to control mycobacterial growth inhibition assay (MGIA) (Exploratory endpoint for immunogenicity outcomes 2) Immunogenic properties of the intervention group will be compared to the control group assessed by the summative ability of specific immune cells to control mycobacterial growth inhibition. Up to week 24
Primary Early Bactericidal Activity (EBA) from day 0 to day 14 Measured as the reduction of bacillary load of M. Tuberculosis based upon Time to detection (TTD) signal in MGIT. Daily between day 0 and day 14 after treatment initiation and RUTI®/placebo vaccination.
Secondary Early Bactericidal Activity (EBA) from 2 to 14 days Measured as the reduction of bacillary load of M. Tuberculosis based upon Time to detection (TTD) signal in MGIT. Difference between each intervention arm and control group. Daily between day 2 and day 14 after treatment initiation and RUTI®/placebo vaccination.
Secondary Early Bactericidal Activity (EBA) from 7 to 14 days Measured as the reduction of the bacillary load of M. Tuberculosis based upon Time to detection (TTD) signal in MGIT. Daily between day 7 and day 14 after treatment initiation and RUTI®/placebo vaccination.
Secondary Early Bactericidal Activity (EBA) from 4 to 24 week Measured as the reduction of the bacillary load of M. Tuberculosis based upon Time to detection (TTD) signal in MGIT At week 4, 8, 16 and 24 after treatment initiation and RUTI®/placebo vaccination
Secondary Hazard ratio for stable culture conversion (SCC). Difference between each intervention arm and control group. 24 weeks of TB treatment
Secondary Rate of Change in Time to Sputum Culture Positivity (TTP) in Liquid Culture Media (Days 0-14). Difference between each intervention arm and control group. 14 days
Secondary Rate of Change in Time to Sputum Culture Positivity (TTP) in Liquid Culture Media (week 4, 8, 16 and 24 ) Difference between each intervention arm and control group. Up to week 24
Secondary The proportion of patients with AEs between each intervention arm and the control group. Difference of patients with AEs between each intervention arm and control group. Up to week 24
Secondary The proportion of patients with SAEs between each intervention arm and the control group Difference of patients with SAEs between each intervention arm and control group. Up to week 24
Secondary Proportion of patients with CLINICAL, X-ray or LABORATORY worsening Difference of patients with Clinical, X-ray or Laboratory worsening between each intervention arm and control group. Through study completion, an average of 24 weeks
Secondary Proportion of patients with improvement of clinical signs and symptoms, Bandim TB score Difference of patients with improvement of clinical signs and symptoms between intervention and control group. At weeks 2, 8, 24
Secondary Number of patients with improvement of Health-related Quality of Life (HRQoL) comparing baseline measure with that over the course of therapy. Difference f patients with improvement of HRQoL between each intervention arm and control group. At week 8, week 24
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2